Tags : Existing

COVID-19 Pharma

Vir and Alnylam Expand Their Existing Collaboration to Develop RNAi

Shots: The collaboration will evaluate RNAi therapeutics targeting three host factors required for SARS-CoV-2 infection, including ACE2 and TMPRSS2. The third target is expected to emerge from Vir’s ongoing genomics efforts for identifying novel host factors relevant to COVID-19 Under the amended collaboration, Vir will be responsible for the development of selected DCs and the […]Read More


Xiangxue Signs an Exclusive License Agreement with Athenex to Expand

Shots: Athenex to receive $30M up front, ~$170M milestones and royalties on sales of licensed products in China, Hong Kong and Macao. Xiangxue to get exclusive license to develop & commercialize Athenex’s oral Paclitaxel, oral Irinotecan and Tirbanibulin ointment for the treatment of actinic keratosis (AK) in licensed territories The collaboration represents the expansion of […]Read More


Kyowa Kirin Signs Two Agreement with Ardelyx to Expand its

Shots: As per the first agreement, Ardelyx to receive $10M for research and is eligible to receive ~10.5M upfront and up to $500M as development & commercialization milestone and will execute research in collaboration with Kyowa Kirin for only two targets Following the end of the research period, Kyowa Kirin to get an option to […]Read More


Leo Pharma and MorphoSys Expands Their Existing Collaboration of Antibody-Based

Shots: Leo Pharma(Leo) will select the targets and MorphoSys will recognize lead molecules using peptide technology platform. Leo Pharma will either develop the lead molecules or use them to design the other drug candidates Leo will have exclusive, worldwide rights and take care of the development and commercialization of any drugs developed in dermatology. MorphoSys […]Read More